Posted by Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases, announced the dosing of the first patient in a Phase 2b clinical trial evaluating the efficacy and safety of OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a unique topical formulation of dexamethasone based on the Company’s proprietary Solubilizing NanoParticle (SNP) technology platform and has the potential to become the first once daily topical steroid to treat inflammation and pain following ocular surgery.
The prospective, multi-center, randomized Phase 2b clinical trial will evaluate the efficacy and safety of OCS-01 in the management of pain and inflammation following cataract surgery. The study is being conducted in 20 specialized ocular surgery centers in the U.S.
Oculis is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide. These topical treatments represent an unprecedented technical advance for patients with back-of-the-eye diseases that are currently managed only by intra-ocular injections or implants; while topical treatments for front-of-the-eye disease are designed to improve patient outcomes by increasing drug bioavailability, reducing dosing frequency and improving patient compliance.
The company’s leading clinical candidates include, OCS-01 and OCS-02. OCS-01 is currently in clinical trial in patients with DME and post-cataract patients. If approved in DME, OCS-01 has the potential to provide a new non-invasive treatment option for DME patients. OCS-02 is a novel topical anti-TNF alpha antibody in Phase 2 for inflammatory eye diseases and was in-licensed from Novartis.